Bridgeway Capital Management LLC acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 60,000 shares of the company's stock, valued at approximately $159,000. Bridgeway Capital Management LLC owned 0.21% of Aerovate Therapeutics at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Ieq Capital LLC bought a new position in shares of Aerovate Therapeutics during the 4th quarter valued at approximately $38,000. Russell Investments Group Ltd. boosted its stake in Aerovate Therapeutics by 110.7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,184 shares of the company's stock worth $40,000 after purchasing an additional 7,977 shares during the period. Barclays PLC boosted its stake in Aerovate Therapeutics by 310.8% in the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock worth $39,000 after purchasing an additional 14,354 shares during the period. XTX Topco Ltd bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $63,000. Finally, Harvest Investment Services LLC bought a new position in Aerovate Therapeutics in the 4th quarter worth approximately $63,000.
Aerovate Therapeutics Stock Down 0.7%
AVTE stock traded down $0.06 during midday trading on Monday, hitting $7.35. The company's stock had a trading volume of 302,580 shares, compared to its average volume of 18,406. Aerovate Therapeutics, Inc. has a 12 month low of $43.75 and a 12 month high of $884.98. The firm has a market capitalization of $212.89 million, a price-to-earnings ratio of -2.46 and a beta of 0.95. The company has a 50 day moving average of $65.86 and a two-hundred day moving average of $81.40.
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $7.35. On average, analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.
Aerovate Therapeutics Announces Dividend
The firm also recently declared a dividend, which was paid on Monday, April 28th. Shareholders of record on Friday, April 25th were paid a $84.00 dividend. The ex-dividend date of this dividend was Tuesday, April 29th.
Aerovate Therapeutics Profile
(
Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Further Reading
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
